JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - GUARDANT HEALTH INC
Explicit Guidance:
- Free Cash Flow Break-even: Targeting Q4 2027 as the break-even point for the total company; screening business expected to reduce cash burn in H2 2027.
- ADLT Coverage: Base case expectation for Garden 360 ADLT (Advances in Laboratory Tests) coverage implementation on April 1, 2028.
- Cost per Test (SHIELD): Target to reduce Cost of Goods Sold (COGS) to $200 per test by the end of 2028.
- Salesforce Expansion: Plan to scale the sales team to a steady state of 600–700 representatives by 2027 (currently north of 400).
- Revenue Timing: Initial commercial revenue accrual from 100 million covered lives (United, Cigna, Anthem) expected in H2 2027 as payment contracts finalize; volume boost expected in 2027.
Business-Segment Outlook:
- Garden 360 (Liquid): Launch of the FDA-approved "Liquid CDX" version expected in 2028; 11 new "Smart Apps" (including immune checkpoint inhibitor prediction and PD-L1 characterization) already launched with more in pipeline.
- Garden 360 (Tissue): Submission for FDA approval expected, with approval anticipated in 2028; sequential growth in tissue volumes was highest seen in Q2–Q3.
- SHIELD (Screening): Expected to grow beyond current testing of ~333k run rate to capture a subset of the 54M unscreened patient population; early DTC pilot results in Q2 showed "fantastic" KPIs, with plans to scale investment and national DTC strategy in 2027.
- Reveal Ultra: Clinical launch with Pharma partners planned for end of year; positioned to capture both tissue-free (speed, no biopsy needed) and tumor-informed (deep sensitivity) use cases.
- Biopharma Data: Targeting 1 exabyte of patient data within a couple of years; fastest growing segment with potential for early treatment response monitoring in trials using methylation/epigenomic data.
- Non-Oncology Expansion: Leveraging SHIELD and REVEAL databases to screen for liver, kidney, and other diseases beyond oncology, aiming for multi-disease blood tests in annual checkups.
Market and Competitive Outlook:
- Volume Growth: Anticipated "millions of tests" opportunity in the U.S. for therapy monitoring and serial testing among the ~1M late-stage cancer patients.
- Market Convergence: Long-term view that the market for "therapy response monitoring" and "MRD" will converge as drugs move into earlier lines of therapy and testing becomes part of a unified continuum.
- Competitive Moat: Belief in owning both modalities (tissue and liquid) with tissue test now covering genomics, transcriptomics, and methylation; low Q&S rates cited as a differentiator.
- PCP Channel: Strategic prioritization of scaling a primary care provider (PCP) channel for non-oncology applications, though this remains a research/pipeline initiative rather than near-term revenue.
Macro / Industry Outlook:
- USPSCF Guidelines: Monitoring November panel meetings for potential USPSCF guideline inclusion to secure $0 out-of-pocket access; currently 80% of lives have coverage via other mechanisms.
- Reimbursement Mechanics: Anticipates initial revenue impact from new payer contracts (United effective August, others in January) to be driven by volume first, with ASP consistency and full financial recognition occurring in H2 2027.
- Regulatory Path: FDA approvals for SHIELD low-cost/high-throughput automation expected late 2027; ADLT coverage for Garden 360 expected April 2028 based on the SHIELD approval timeline.
Strategic Initiatives:
- Automation Investment: Heavy investment in laboratory automation to reduce labor costs and drive COGS down further, pending FDA approval in late 2027.
- DTC Scaling: Reinvesting gross profit from DTC pilots into a national Direct-to-Consumer strategy and influencer program in 2027 to expand the patient funnel.
- Data Utilization: Converting hundreds of thousands of real-world patient outcomes into predictive "Smart Apps" for the Garden 360 platform.
Risks and Headwinds to Outlook:
- Reimbursement Delays: Potential delay in USPSCF guidelines could limit $0 out-of-pocket access for a broader patient population, impacting utilization of preventive services.
- Payment History: Time required to build consistent collection history and negotiate ASPs with new payers (United, Cigna, Anthem) may delay full revenue recognition.
- Regulatory Timing: Automation approvals and ADLT implementation timelines are subject to FDA and legislative processing times.
- Education Requirements: Continued physician education needed for the ESR-1 launch and tissue-test adoption to drive full volume.
Management Tone on the Future:
- Confidence: High confidence in hitting Q4 2027 FCF break-even and $200 COGS target by end of 2028.
- Optimism: Described as "scratching the surface" regarding the 100M covered lives opportunity; "excited" about the convergence of precision medicine and real-world data.
- No Risk of Slip: Explicitly stated "no risk" regarding the April 1, 2028 ADLT base case assumption.
- Strategic Shift: Noting a shift from "tissue vs. liquid" debate to a strategy of "owning both" modalities to capture the full standard of care.
Miscellaneous:
- SHIELD Volumes: Q3 saw 83,000 tests with 100M covered lives; COGS dropped from >$1,000 at launch to ~$330 in Q3.
- Data Scale: Current database contains hundreds of thousands of patients with EMR and claims data; targeting 1 exabyte soon.
- Market Size: Estimation of 17–18 million annual testing opportunities within the unscreened population.
- Company
- GUARDANT HEALTH INC
- Keywords
- GUARDANT HEALTH INC